Houssam E Mardini1, Philip Westgate, Alla Y Grigorian. 1. Lexington VA Medical Center, University of Kentucky College of Medicine, 800 Rose Street, Room MN649, Lexington, KY, 40536, USA, mardinihe@uky.edu.
Abstract
AIM: To provide an estimate of the prevalence of celiac disease by race/ethnic origin in large sample of US population. METHODS: Data from the 2009-2010 and 2011-2012 NHANES were combined and analyzed. The NHANES is a nationally representative survey with oversampling of certain minorities. Sample-based frequencies were reported and weighted frequencies were used to estimate prevalence. RESULTS: A total of 14,701 participants were checked for tissue transglutaminase (tTG) and endomysial (EMA) IgA antibodies. Seventy-four participants had positive tTG and/or EMA corresponding to prevalence of 0.79 % (95 % CI 0.54-1.04 %). Non-Hispanic white were more likely to be positive for both compared with other races (72.0 vs 31.7 %; p = 0.010) and less likely to be weakly positive for tTG but positive for EMA (3.6 vs 26.4 %; p = 0.03). The prevalence of positive serology according to race was as follows: 1.08 % (95 % CI 0.70-1.45 %) in non-Hispanic white, 0.23 % (95 % CI 0.03-0.43 %) in Mexican, 0.22 % (95 % CI 0.01-0.44 %) in non-Hispanic black, 0.38 % (95 % CI 0.00-0.89 %) in "other Hispanic," and 0.15 % (95 % CI 0.00-0.34 %) in other races including multiracial and undeterminable in non-Hispanic Asian due to the presence of only one positive EMA test. 0.9 % of the NHANES sample participants followed gluten-free diet. Of this group of participants, 85 % were never diagnosed with celiac disease and 99 % of them had negative celiac disease serology. CONCLUSIONS: Potentially 0.79 % of the general US population demonstrate serologic evidence of celiac disease autoimmunity. The prevalence is 4-8 times higher among non-Hispanic white compared with other races. Close to 1 % of the population is electively following gluten-free diet despite having little evidence of the disease.
AIM: To provide an estimate of the prevalence of celiac disease by race/ethnic origin in large sample of US population. METHODS: Data from the 2009-2010 and 2011-2012 NHANES were combined and analyzed. The NHANES is a nationally representative survey with oversampling of certain minorities. Sample-based frequencies were reported and weighted frequencies were used to estimate prevalence. RESULTS: A total of 14,701 participants were checked for tissue transglutaminase (tTG) and endomysial (EMA) IgA antibodies. Seventy-four participants had positive tTG and/or EMA corresponding to prevalence of 0.79 % (95 % CI 0.54-1.04 %). Non-Hispanic white were more likely to be positive for both compared with other races (72.0 vs 31.7 %; p = 0.010) and less likely to be weakly positive for tTG but positive for EMA (3.6 vs 26.4 %; p = 0.03). The prevalence of positive serology according to race was as follows: 1.08 % (95 % CI 0.70-1.45 %) in non-Hispanic white, 0.23 % (95 % CI 0.03-0.43 %) in Mexican, 0.22 % (95 % CI 0.01-0.44 %) in non-Hispanic black, 0.38 % (95 % CI 0.00-0.89 %) in "other Hispanic," and 0.15 % (95 % CI 0.00-0.34 %) in other races including multiracial and undeterminable in non-Hispanic Asian due to the presence of only one positive EMA test. 0.9 % of the NHANES sample participants followed gluten-free diet. Of this group of participants, 85 % were never diagnosed with celiac disease and 99 % of them had negative celiac disease serology. CONCLUSIONS: Potentially 0.79 % of the general US population demonstrate serologic evidence of celiac disease autoimmunity. The prevalence is 4-8 times higher among non-Hispanic white compared with other races. Close to 1 % of the population is electively following gluten-free diet despite having little evidence of the disease.
Authors: Carlo Catassi; Debby Kryszak; Bushra Bhatti; Craig Sturgeon; Kathy Helzlsouer; Sandra L Clipp; Daniel Gelfond; Elaine Puppa; Anthony Sferruzza; Alessio Fasano Journal: Ann Med Date: 2010-10 Impact factor: 4.709
Authors: Jonas F Ludvigsson; Daniel A Leffler; Julio C Bai; Federico Biagi; Alessio Fasano; Peter H R Green; Marios Hadjivassiliou; Katri Kaukinen; Ciaran P Kelly; Jonathan N Leonard; Knut Erik Aslaksen Lundin; Joseph A Murray; David S Sanders; Marjorie M Walker; Fabiana Zingone; Carolina Ciacci Journal: Gut Date: 2012-02-16 Impact factor: 23.059
Authors: Daniel Leffler; Detlef Schuppan; Kumar Pallav; Robert Najarian; Jeffery D Goldsmith; Joshua Hansen; Toufic Kabbani; Melinda Dennis; Ciarán P Kelly Journal: Gut Date: 2012-05-22 Impact factor: 23.059
Authors: C Hischenhuber; R Crevel; B Jarry; M Mäki; D A Moneret-Vautrin; A Romano; R Troncone; R Ward Journal: Aliment Pharmacol Ther Date: 2006-03-01 Impact factor: 8.171
Authors: Alberto Rubio-Tapia; Ivor D Hill; Ciarán P Kelly; Audrey H Calderwood; Joseph A Murray Journal: Am J Gastroenterol Date: 2013-04-23 Impact factor: 10.864
Authors: Joseph A Murray; Carol Van Dyke; Matthew F Plevak; Ross A Dierkhising; Alan R Zinsmeister; L Joseph Melton Journal: Clin Gastroenterol Hepatol Date: 2003-01 Impact factor: 11.382
Authors: Edwin Liu; Fran Dong; Anna E Barón; Iman Taki; Jill M Norris; Brigitte I Frohnert; Edward J Hoffenberg; Marian Rewers Journal: Gastroenterology Date: 2017-02-07 Impact factor: 22.682
Authors: Thomas Spinell; Francesco DeMayo; Matthew Cato; Ashley Thai; Eva J Helmerhorst; Peter H R Green; Benjamin Lebwohl; Ryan T Demmer Journal: J Clin Periodontol Date: 2018-01-11 Impact factor: 8.728
Authors: Marisa G Stahl; Cristy Geno Rasmussen; Fran Dong; Kathleen Waugh; Jill M Norris; Judith Baxter; Liping Yu; Andrea K Steck; Brigitte I Frohnert; Edwin Liu; Marian J Rewers Journal: Am J Gastroenterol Date: 2021-01-01 Impact factor: 12.045